CSS
ACET icon

Cubist Systematic Strategies’s Adicet Bio ACET Stock Holding History

Cubist Systematic Strategies’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-775
Closed -$9.36K – 2899
2025
Q1 		$9.36K Sell
775
-7
-0.9% -$100 ﹤0.01% 2765
2024
Q4 		$12K Sell
782
-4,835
-86% -$91.2K ﹤0.01% 2855
2024
Q3 		$129K Sell
5,617
-19,949
-78% -$447K ﹤0.01% 2657
2024
Q2 		$495K Buy
25,566
+22,694
+790% +$608K ﹤0.01% 2132
2024
Q1 		$108K Buy
2,872
+1,651
+135% +$68.3K ﹤0.01% 3244
2023
Q4 		$36.9K Sell
1,221
-763
-38% -$16.6K ﹤0.01% 3305
2023
Q3 		$43.5K Buy
+1,984
New +$70.1K ﹤0.01% 3042
2023
Q2 		– Sell
-3,090
Closed -$285K – 3410
2023
Q1 		$285K Buy
+3,090
New +$388K ﹤0.01% 3031
2022
Q3 		– Sell
-2,783
Closed -$650K – 4383
2022
Q2 		$650K Buy
2,783
+2,745
+7,224% +$603K ﹤0.01% 2846
2022
Q1 		$12K Sell
38
-1,815
-98% -$417K ﹤0.01% 3490
2021
Q4 		$518K Buy
1,853
+1,189
+179% +$204K ﹤0.01% 2425
2021
Q3 		$83K Sell
664
-118
-15% -$14.6K ﹤0.01% 2774
2021
Q2 		$129K Buy
+782
New +$159K ﹤0.01% 2682

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Cubist Systematic Strategies's ACET Position: Q2 2025 in Review

Cubist Systematic Strategies sold out of Adicet Bio (ACET) in Q2 2025, closing a stake of 775 shares — an estimated $9.36K sold.

Cubist Systematic Strategies first reported a position in ACET in Q2 2021 and held it in 13 quarters. The position peaked at $650K in Q2 2022. 49 funds tracked by Wall St. Rank hold ACET as of Q2 2025.

  • Cubist Systematic Strategies reported no remaining Adicet Bio position as of Q2 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 775 Adicet Bio shares in Q2 2025, an estimated $9.36K.
  • Cubist Systematic Strategies first reported a position in Adicet Bio in Q2 2021 and held it in 13 quarters.
  • Cubist Systematic Strategies's Adicet Bio position peaked at $650K in Q2 2022.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2025.

Based on Cubist Systematic Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.